Off-trial access to experimental cancer agents for the terminally ill: Balancing the needs of individuals and society

Journal of Medical Ethics

Volumn 36, Issue 6, 2010, Pages 367-370

  Chahal, Manik ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; NEW DRUG;

ARTICLE; ETHICS; HEALTH CARE DELIVERY; HUMAN; MEDICAL ETHICS; NEOPLASM; PATIENT RIGHT; SOCIAL PSYCHOLOGY; TERMINAL CARE; TERMINALLY ILL PATIENT;

ANTINEOPLASTIC AGENTS; DRUGS, INVESTIGATIONAL; ETHICS, MEDICAL; HEALTH SERVICES ACCESSIBILITY; HUMANS; NEOPLASMS; PATIENT RIGHTS; SOCIAL VALUES; TERMINAL CARE; TERMINALLY ILL;

EID: 77956074260     PISSN: 03066800     EISSN: 14734257     Source Type: Journal    
DOI: 10.1136/jme.2009.032466     Document Type: Article

References (29)

1. Jacobson PD, Parmet WE. A new era of unapproved drugs: the case of Abigail Alliance v Von Eschenbach. JAMA 2007;297:205-8.
2. Caplan A. Is it sound public policy to let the terminally ill access experimental medical innovations? Am J Bioeth 2007;7:1-3.
3. Steinbock B, Arras J, London A. Introduction: moral reasoning in the medical context. In: Steinbock B, Arras J, London A, eds. Ethical issues in modern medicine. 7th edn. New York, NY: McGraw-Hill Companies, Inc, 2009:1-41.
4. The declaration of Helsinki. World Med J 1982;29:86-8.
5. Cox K, McGarry J. Why patients don't take part in cancer clinical trials: an overview of the literature. Eur J Cancer Care (Engl) 2003;12:114-22.
6. Gesme D. Should terminally ill patients have the right to take drugs that pass phase I testing? Yes. BMJ 2007;335:479.
7. Castel P, Negrier S, Boissel JP. Why don't cancer patients enter clinical trials? A review. Eur J Cancer 2006;42:1744-8.
8. Schuklenk U, Lowry C. Terminal illness and access to phase 1 experimental agents, surgeries and devices: reviewing the ethical arguments. Br Med Bull 2009;89:7-22.
9. Jayson G, Harris J. How participants in cancer trials are chosen: ethics and conflicting interests. Nat Rev Cancer 2006;6:330-6.
10. Dunstan G. Should philosophy and medical ethics be left to the experts? In: Bewley SWR, eds. Ethics in obstetrics & gynaecology. London, UK: RCOG Pres, 1994:3-8.
11. Martin DK, Emanuel LL, Singer PA. Planning for the end of life. Lancet 2000;356:1672-6.
12. Dworkin G. The theory and practice of autonomy. Cambridge, MA: Cambridge University Press, 1988.
13. Werth JL Jr. The relationships among clinical depression, suicide, and other actions that may hasten death. Behav Sci Law 2004;22:627-49.
14. Robertson JA. Controversial medical treatment and the right to health care. Hastings Cent Rep 2006;36:15-20.
15. Kleinman I. The right to refuse treatment: ethical considerations for the competent patient. CMAJ 1991;144:1219-22.
16. Society for Clinical Trials Board of Directors. The Society for Clinical Trials opposes US legislation to permit marketing of unproven medical therapies for seriously ill patients. Clin Trials 2006;3:154-7.
17. de Haes H, Koedoot N. Patient centered decision making in palliative cancer treatment: a world of paradoxes. Patient Educ Couns 2003;50:43-9.
18. Levine MN, Guyatt GH, Gent M, et al. Quality of life in stage II breast cancer: an instrument for clinical trials. J Clin Oncol 1988;6:1798-810.
19. Harris J. Consent and end of life decisions. J Med Ethics 2003;29:10-15.
20. Okie S. Access before approvale-a right to take experimental drugs? N Engl J Med 2006;355:437-40.
21. Ellis PM. Attitudes towards and participation in randomised clinical trials in oncology: a review of the literature. Ann Oncol 2000;11:939-45.
22. Bender S, Flicker L, Rhodes R. Access for the terminally ill to experimental medical innovations: a three-pronged threat. Am J Bioeth 2007;7:3-6.
23. Talbott MK. Currents in contemporary ethics. The implications of expanding access to unapproved drugs. J Law Med Ethics 2007;35:316-19.
24. Harris J. Scientific research is a moral duty. J Med Ethics 2005;31:242-8.
25. Callahan D. Bioethics: private choice and common good. Hastings Cent Rep 1994;24:28-31.
26. Evans HM. Should patients be allowed to veto their participation in clinical research? J Med Ethics 2004;30:198-203.
27. Falit BP, Gross CP. Access to experimental drugs for terminally ill patients. JAMA 2008;300:2793-5.
28. Mayer M. Swimming upstream: an advocate reflects on cancer research and social realities. J Clin Oncol 2008;26:2783-6.
29. Comis RL. The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer. Oncologist 2005;10:467-70.